Skip to content
OpenCapital
Get started

Summit Therapeutics SMMT Q3 2025 earnings

Reported October 20, 2025 · Before market open

Diluted EPS-$0.31Miss by $0.13
Revenue estimate$76.5M
EPS estimate-$0.18

Next report

Aug 10, 2026 (In 4 weeks)
Revenue estimate$108.8K
EPS estimate-$0.26

Financials

Q3 2025

Income statement

See full
Net income-$231.8M-312%
EPS (diluted)-$0.31-287%

Balance sheet

See full
Cash & equivalents$4.9M-60.5%
Total debt$5.4M-32.1%
Total equity$192.3M-56.1%
Total assets$261.7M-48.0%

Cash flow

See full
Operating cash flow-$93.1M-207%
CapEx$71.0K+22.4%
Free cash flow-$93.2M-207%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$15.35B-0.2%
Enterprise value$15.35B-0.1%

Returns & leverage

See full
Return on equity-292.5%-439pp
Debt / equity0×0.0×
Current ratio3.8×-4.5×

Versus estimates

Diluted EPS

Q1 2026-$0.24Beat by $0.09Q4 2025-$0.29Miss by $0.19
Q3 2025-$0.31Miss by $0.13
Q2 2025-$0.76Miss by $0.67Q1 2025-$0.09Beat by $0.00Q4 2024-$0.08Beat by $0.00

Ask the moment Summit Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Summit Therapeutics report Q3 2025 earnings?
Summit Therapeutics (SMMT) reported Q3 2025 earnings on October 20, 2025 before market open.
What were Summit Therapeutics's Q3 2025 revenue and EPS?
Summit Therapeutics reported diluted EPS of $-0.31 for Q3 2025.
Did Summit Therapeutics beat estimates in Q3 2025?
EPS missed the consensus estimate of $-0.18 by $0.13.
How did Summit Therapeutics's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS declined 287.5% from $-0.08.
Where can I find Summit Therapeutics's Q3 2025 SEC filings?
You can read the 10-Q periodic report (0001599298-25-000159) directly on SEC EDGAR. The filing index links above go to sec.gov.